Shots:

• The CHMP’s recommendation is based on P-III KATHERINE study assessing Kadcyla vs Herceptin as an adjuvant therapy in patients with HER2+ early breast cancer with the residual invasive disease after neoadjuvant treatment which included Herceptin and Taxane-based CT
• The P-III KATHERINE study results: reduction in iDFS by 50%; @3yrs. iDFS (88.3% vs 77.0%) showing absolute improvement of 11.3%; AEs (25.7% vs 15.4%)
• Kadcyla (trastuzumab emtansine) is an ADC- a combination of trastuzumab and DM1- delivering CT directly to HER2+ cancer cells. It has received approval in 104 countries including the US & EU for HER2+ m-breast cancer and is developed using ADC technology licensed from ImmunoGen

Click here to­ read full press release/ article 

Ref: Roche | Image: Roche